Abstract

With a dual-labeled imaging agent, Optical/CT/PET primary prostate cancer imaging was performed in a Siemens Inveon scanner. PET-based imaging validation shows the potential of the developed fluorescence tomography for preclinical research.

© 2012 OSA

PDF Article